

# Anna Salvetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8142334/publications.pdf>

Version: 2024-02-01

76  
papers

2,640  
citations

147801

31  
h-index

197818

49  
g-index

83  
all docs

83  
docs citations

83  
times ranked

2594  
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors Influencing Recombinant Adeno-Associated Virus Production. <i>Human Gene Therapy</i> , 1998, 9, 695-706.	2.7	239
2	Lack of an Immune Response against the Tetracycline-Dependent Transactivator Correlates with Long-Term Doxycycline-Regulated Transgene Expression in Nonhuman Primates after Intramuscular Injection of Recombinant Adeno-Associated Virus. <i>Journal of Virology</i> , 2002, 76, 11605-11611.	3.4	137
3	Control of Erythropoietin Delivery by Doxycycline in Mice After Intramuscular Injection of Adeno-Associated Vector. <i>Blood</i> , 1998, 92, 1512-1517.	1.4	118
4	Immediate and Long-Term Safety of Recombinant Adeno-associated Virus Injection into the Nonhuman Primate Muscle. <i>Molecular Therapy</i> , 2001, 4, 559-566.	8.2	112
5	Viruses and the nucleolus: The fatal attraction. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 840-847.	3.8	88
6	AAV Vectors Vaccines Against Infectious Diseases. <i>Frontiers in Immunology</i> , 2014, 5, 5.	4.8	83
7	Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. <i>Journal of Gene Medicine</i> , 2000, 2, 260-268.	2.8	81
8	Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno-Associated Virus Production and Their in Vivo Persistence after Vector Delivery. <i>Molecular Therapy</i> , 2005, 12, 744-753.	8.2	81
9	A Versatile and Scalable Two-Step Ion-Exchange Chromatography Process for the Purification of Recombinant Adeno-associated Virus Serotypes-2 and -5. <i>Molecular Therapy</i> , 2002, 6, 678-686.	8.2	81
10	Protection Against Henipavirus Infection by Use of Recombinant Adeno-Associated Virus "Vector Vaccines. <i>Journal of Infectious Diseases</i> , 2013, 207, 469-478.	4.0	72
11	Helper Functions Required for Wild Type and Recombinant Adeno- Associated Virus Growth. <i>Current Gene Therapy</i> , 2005, 5, 265-271.	2.0	70
12	Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection. <i>Journal of Hepatology</i> , 2019, 71, 1086-1098.	3.7	62
13	Improvement of erythropoiesis in $\beta^2$ -thalassemic mice by continuous erythropoietin delivery from muscle. <i>Blood</i> , 2000, 95, 2793-2798.	1.4	59
14	Functional Characterization of Adenoviral/Retroviral Chimeric Vectors and Their Use for Efficient Screening of Retroviral Producer Cell Lines. <i>Human Gene Therapy</i> , 1999, 10, 189-200.	2.7	58
15	Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. <i>Scientific Reports</i> , 2018, 8, 5390.	3.3	57
16	Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity. <i>Scientific Reports</i> , 2019, 9, 3631.	3.3	57
17	Functional Retroviral Vector for Gene Therapy of Xeroderma Pigmentosum Group D Patients. <i>Human Gene Therapy</i> , 1995, 6, 1307-1315.	2.7	54
18	Improving rAAV production and purification: towards the definition of a scaleable process. <i>Journal of Gene Medicine</i> , 2004, 6, S223-S228.	2.8	53

#	ARTICLE	IF	CITATIONS
19	Herpes simplex virus 1 induces egress channels through marginalized host chromatin. <i>Scientific Reports</i> , 2016, 6, 28844.	3.3	53
20	Characterization of AAV vector particle stability at the single-capsid level. <i>Journal of Biological Physics</i> , 2018, 44, 181-194.	1.5	53
21	Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. <i>Antiviral Research</i> , 2017, 145, 14-19.	4.1	49
22	Evidence for Packaging of rep-cap Sequences into Adeno-Associated Virus (AAV) Type 2 Capsids in the Absence of Inverted Terminal Repeats: a Model for Generation of rep-Positive AAV Particles. <i>Journal of Virology</i> , 2003, 77, 776-781.	3.4	48
23	Nuclear Functions of Nucleolin through Global Proteomics and Interactomic Approaches. <i>Journal of Proteome Research</i> , 2016, 15, 1659-1669.	3.7	48
24	Novel cis-Acting Replication Element in the Adeno-Associated Virus Type 2 Genome Is Involved in Amplification of Integrated rep-cap Sequences. <i>Journal of Virology</i> , 2001, 75, 9991-9994.	3.4	47
25	Hyaluronidase enhances recombinant adeno-associated virus (rAAV)-mediated gene transfer in the rat skeletal muscle. <i>Gene Therapy</i> , 2000, 7, 1417-1420.	4.5	44
26	Definition of Herpes Simplex Virus Type 1 Helper Activities for Adeno-Associated Virus Early Replication Events. <i>PLoS Pathogens</i> , 2009, 5, e1000340.	4.7	42
27	Phenotypic rescue after adeno-associated virus-mediated delivery of 4-sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VI. <i>Journal of Gene Medicine</i> , 2002, 4, 613-621.	2.8	38
28	Identification of a negative element in the human vimentin promoter: modulation by the human T-cell leukemia virus type I Tax protein.. <i>Molecular and Cellular Biology</i> , 1993, 13, 89-97.	2.3	37
29	Characterization of Pattern Recognition Receptor Expression and Functionality in Liver Primary Cells and Derived Cell Lines. <i>Journal of Innate Immunity</i> , 2018, 10, 339-348.	3.8	36
30	A Versatile and Scalable Two-Step Ion-Exchange Chromatography Process for the Purification of Recombinant Adeno-associated Virus Serotypes-2 and -5. <i>Molecular Therapy</i> , 2002, 6, 678-686.	8.2	35
31	Control of Erythropoietin Delivery by Doxycycline in Mice After Intramuscular Injection of Adeno-Associated Vector. <i>Blood</i> , 1998, 92, 1512-1517.	1.4	33
32	Characterization of Adenovirus-Induced Inverted Terminal Repeat-Independent Amplification of Integrated Adeno-Associated Virus rep-cap Sequences. <i>Journal of Virology</i> , 2001, 75, 375-383.	3.4	31
33	Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines. <i>Journal of Gene Medicine</i> , 2004, 6, 555-564.	2.8	28
34	Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production. <i>PLoS Pathogens</i> , 2020, 16, e1008593.	4.7	28
35	Adeno-Associated Virus Type 2 Modulates the Host DNA Damage Response Induced by Herpes Simplex Virus 1 during Coinfection. <i>Journal of Virology</i> , 2012, 86, 143-155.	3.4	27
36	The Cellular TATA Binding Protein Is Required for Rep-Dependent Replication of a Minimal Adeno-Associated Virus Type 2 p5 Element. <i>Journal of Virology</i> , 2005, 79, 11082-11094.	3.4	25

#	ARTICLE	IF	CITATIONS
37	Herpes Simplex Virus Type 1 ICPO Protein Mediates Activation of Adeno-Associated Virus Type 2 rep Gene Expression from a Latent Integrated Form. <i>Journal of Virology</i> , 2004, 78, 10977-10986.	3.4	23
38	Capsid Engineering Overcomes Barriers Toward Adeno-Associated Virus Vector-Mediated Transduction of Endothelial Cells. <i>Human Gene Therapy</i> , 2019, 30, 1284-1296.	2.7	23
39	RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes. <i>Gut</i> , 2022, 71, 991-1005.	12.1	23
40	Identification of Rep-Associated Factors in Herpes Simplex Virus Type 1-Induced Adeno-Associated Virus Type 2 Replication Compartments. <i>Journal of Virology</i> , 2010, 84, 8871-8887.	3.4	22
41	Inhibition of Herpes Simplex Virus Type 1 Replication by Adeno-Associated Virus Rep Proteins Depends on Their Combined DNA-Binding and ATPase/Helicase Activities. <i>Journal of Virology</i> , 2010, 84, 3808-3824.	3.4	21
42	Gene therapy of lysosomal storage disorders. <i>British Medical Bulletin</i> , 1995, 51, 106-122.	6.9	19
43	In Vivo Delivery of Human $\alpha$ -L-Iduronidase in Mice Implanted with Neo-Organs. <i>Human Gene Therapy</i> , 1995, 6, 1153-1159.	2.7	19
44	Hepatitis B virus infection enhances susceptibility toward adeno-associated viral vector transduction <i>in vitro</i> and <i>in vivo</i> . <i>Hepatology</i> , 2014, 59, 2110-2120.	7.3	19
45	Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer. <i>Frontiers in Microbiology</i> , 2011, 2, 199.	3.5	18
46	Reduced Expression of Hippocampal GluN2A-NMDAR Increases Seizure Susceptibility and Causes Deficits in Contextual Memory. <i>Frontiers in Neuroscience</i> , 2021, 15, 644100.	2.8	17
47	Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector. <i>Molecular Therapy</i> , 2016, 24, 87-95.	8.2	15
48	Impact of the Interaction between Herpes Simplex Virus Type 1 Regulatory Protein ICPO and Ubiquitin-Specific Protease USP7 on Activation of Adeno-Associated Virus Type 2 rep Gene Expression. <i>Journal of Virology</i> , 2006, 80, 3650-3654.	3.4	11
49	Impact of the MRN Complex on Adeno-Associated Virus Integration and Replication during Coinfection with Herpes Simplex Virus 1. <i>Journal of Virology</i> , 2015, 89, 6824-6834.	3.4	11
50	SRSF10: an atypical splicing regulator with critical roles in stress response, organ development, and viral replication. <i>Rna</i> , 2021, 27, 1302-1317.	3.5	11
51	Loss of hepatitis D virus infectivity upon farnesyl transferase inhibitor treatment associates with increasing RNA editing rates revealed by a new RT-ddPCR method. <i>Antiviral Research</i> , 2022, 198, 105250.	4.1	11
52	Evidence for long-term association of virion-delivered HBV core protein with cccDNA independently of viral protein production. <i>JHEP Reports</i> , 2021, 3, 100330.	4.9	10
53	Interplay Between CMGC Kinases Targeting SR Proteins and Viral Replication: Splicing and Beyond. <i>Frontiers in Microbiology</i> , 2021, 12, 658721.	3.5	9
54	Immunological Tolerance to Muscle Autoantigens Involves Peripheral Deletion of Autoreactive CD8+ T Cells. <i>PLoS ONE</i> , 2012, 7, e36444.	2.5	9

#	ARTICLE	IF	CITATIONS
55	Factors influencing helper-independent adeno-associated virus replication. <i>Virology</i> , 2012, 432, 1-9.	2.4	8
56	Gene Transfer into the Kidney: Current Status and Limitations. <i>Nephron</i> , 1997, 77, 139-151.	0.6	7
57	Fast Differentiation of HepaRG Cells Allowing Hepatitis B and Delta Virus Infections. <i>Cells</i> , 2020, 9, 2288.	4.1	7
58	Antiviral Activity of PLK1-Targeting siRNA Delivered by Lipid Nanoparticles in HBV-Infected Hepatocytes. <i>Antiviral Therapy</i> , 2020, 25, 151-162.	1.0	7
59	Intracellular route and biological activity of exogenously delivered Rep proteins from the adeno-associated virus type 2. <i>Virology</i> , 2005, 335, 252-263.	2.4	6
60	Stable Producer Cell Lines for Adeno-Associated Virus (AAV) Assembly. <i>Cold Spring Harbor Protocols</i> , 2010, 2010, pdb.prot5496.	0.3	6
61	Inhibitory Effect of IL-1 $\beta$ on HBV and HDV Replication and HBs Antigen-Dependent Modulation of Its Secretion by Macrophages. <i>Viruses</i> , 2022, 14, 65.	3.3	6
62	Relative Influence of the Adeno-Associated Virus (AAV) Type 2 p5 Element for Recombinant AAV Vector Site-Specific Integration. <i>Journal of Virology</i> , 2008, 82, 2590-2593.	3.4	4
63	Investigating the neuroprotective effect of AAV-mediated $\beta$ -synuclein overexpression in a transgenic model of synucleinopathy. <i>Scientific Reports</i> , 2018, 8, 17563.	3.3	4
64	Optical Quantification by Nanopores of Viruses, Extracellular Vesicles, and Nanoparticles. <i>Nano Letters</i> , 2022, 22, 3651-3658.	9.1	4
65	Efficiency of adeno-associated virus type-2 vectors in non-human primate Schwann cells. <i>NeuroReport</i> , 2005, 16, 1757-1762.	1.2	3
66	Inducers of the NF- $\kappa$ B pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity in vitro. <i>JHEP Reports</i> , 2022, 4, 100415.	4.9	3
67	Stiffness heterogeneity of small viral capsids. <i>Physical Review E</i> , 2021, 104, 064408.	2.1	3
68	Delivery of therapeutic proteins from genetically-modified cells. <i>Restorative Neurology and Neuroscience</i> , 1995, 8, 67-69.	0.7	0
69	The Journal of Gene Medicine 2000 Young Investigator Award. <i>Journal of Gene Medicine</i> , 2001, 3, 96-97.	2.8	0
70	Antiviral properties and liver specific delivery of a TLR1/2 ligand in HBV-infected in vitro and in vivo models. <i>Journal of Hepatology</i> , 2018, 68, S772.	3.7	0
71	Identification of hepatitis B virus core protein nuclear interacting factors points to RNA binding proteins as major regulators of HBV replication. <i>Journal of Hepatology</i> , 2018, 68, S766.	3.7	0
72	Neuronal expression of a single-chain variable fragment antibody against A $\beta$ oligomers protects synapses and rescues memory in Alzheimer models. <i>Alzheimer's and Dementia</i> , 2020, 16, e041530.	0.8	0

#	ARTICLE	IF	CITATIONS
73	10: ADENO-ASSOCIATED VIRUS (AAV) VECTORS. ICP Textbooks in Biomolecular Sciences, 2014, , 151-164.	0.1	0
74	ANALYSIS OF GENE TRANSFER EFFICACY IN RAT ISLETS WITH ADENO VIRUS, ADENO-ASSOCIATED VIRUS AND BACULOVIRUS.. Transplantation, 1999, 67, S63.	1.0	0
75	ADENO-ASSOCIATED VIRUS (AAV) VECTORS. , 2019, , 167-180.		0
76	Les vecteurs AAV pour le transfert de g <sup>ne</sup> in vivo ou comment un petit virus devient grand. Virologie, 2013, 17, 343-353.	0.1	0